Company Overview

Hemosol is an integrated biopharmaceutical developer and manufacturer of biologics, particularly blood-related protein based therapeutics. The Company is deploying a novel technology, Plasma Protein Chromatography (PPC), which has the potential to change the business dynamics of the therapeutic plasma proteins sector. Hemosol will initially be producing three proteins to be taken to market Immune Globulin Intravenous 10% (IGIV), Alpha 1 Proteinase Inhibitor (A1PI) and van Willebrand Factor /Factor VIII (vWF/FVIII).

The Company also continues to develop its rich and diverse therapeutic pipeline that includes three technology platforms Oxygen Therapeutics for the treatment of high volume blood loss; Drug Delivery for the treatment of Hepatitis C and liver cancer; and Cell Therapeutics for the treatment of chronic myelogenous leukemia and chemotherapy-induced anemia.

In addition to these initiatives, Hemosol provides contract manufacturing services to other organizations. The Company recently received a Health Canada license for its aseptic vial filling suite. The vial filling line can process vials from 1mL in size up to 200mL. Hemosol is also fully equipped to perform sterile filling operations into IV transfusion bags up to 500mL in size. In the provision of these services Hemosol is focusing on projects that are specific to natural derived proteins and related therapies.

Company Information

Additional Details

Legal Name: Hemosol LP

Number of Employees: 80

Contacts

Services

• Biotechnology
• Contract Manufacturing

  Hemosol provides contract manufacturing services to biotechnology companies focussing on the purification and fill/finish of natural derived proteins.

Products

• Cell Therapeutics - Stem Cells
• Drug Delivery

  Hemosol has developed a new and innovative drug delivery system, designed to improve the targeted delivery of therapeutic drugs to the liver. There are currently three products in development: HRC 201 for the imaging, diagnosis and treament of liver disease; HRC 203 for the treatment of hepatitis C virus (HCV) infection; and HRC 204 for the targeted delivery of chemotherapeutic drugs to treat liver cancer.

  Hemosol is seeking outlicensing and/or partnering opportunities for this new class of biotherapeutic compounds that possess ehnaced efficacy and safety in the treatment of liver disease.

• Oxygen Therapeutics

  Hemosol has developed a second generation oxygen therapeutic (HRC 101), a novel dual function hemoglobin-based oxygen carrier that delivers oxygen and replaces lost blood volume in a range of surgical and trauma settings.

  Hemosol is looking for outlicensing and/or partnering opportunities for this new drug candidate.

• Research And Development

  Research and development of artificial blood (oxygen therapeutics) and other hemoglobin-based blood products, including stem cell research.

• Therapeutic Proteins

  Hemosol is implementing a novel process (Plasma Protein Chromatography) for the production of plasma derived therapeutic proteins. The first protein product the Company will advance through the clinical development and regulatory process is Immune Globulin Intravenous 10% (IGIV). Hemosol expects to file the IND in late 2005 or early 2006 for commercial launch in 2008.

  Hemosol also intends to pursue regulatory approval for Alpha 1 Proteinase Inhibitor (A1PI) and von Willebrand Factor/Factor VIII beginning in 2006.

  Hemosol has completed pre-commercial pilot scale runs for the extraction of all three protein products at a 30-litre scale and results to date have demonstrated increased production yields of all three protein products ranging from 30-450% greater than current industry averages depending on the protein.

NAICS Categories

• 325410 Pharmaceutical and Medicine Manufacturing
• 541710 Research and Development in the Physical, Engineering and Life Sciences

Additional Information